NEVANAC 0.1 %
NEPAFENAC : 0.1 % · DIN 02308983 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is NEVANAC?
NEVANAC 0.1 % contains NEPAFENAC : 0.1 %. It is listed in the Health Canada Drug Product Database under DIN 02308983, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SUSPENSION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 17-Sep-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NEVANAC used for?
Management of pain and inflammation associated with cataract surgery.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02308983 |
|---|---|
| Brand name | NEVANAC |
| Generic / active ingredient | NEPAFENAC : 0.1 % |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 0.1 % |
| Dosage form | SUSPENSION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01BC10 NEPAFENAC |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Sep-2018 |
How is it administered?
Shake well. One drop in the affected eye(s) three-times-daily beginning 1 day prior to surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 2°C - 30°C. Discard 28 days after opening.
How is it supplied?
5 mL supplied in an 8 mL round low density polyethylene bottle with a dispensing plug and polypropylene cap.
Contraindications
Hypersensitivity to nepafenac, any ingredient in the formulation, or other nonsteroidal anti-inflammatory drugs (NSAIDs).
Warnings and precautions
Topical NSAIDs may slow/delay healing. Potential for increased bleeding time. Risk of keratitis and corneal adverse events (thinning, erosion, perforation) which may be sight-threatening.
What can be used instead?
Other Canadian products sharing ATC code S01BC10 NEPAFENAC. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ILEVRO | 0.3 % | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02411393 |
Who else supplies NEPAFENAC worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NEPAFENAC appears in 11 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.